• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease.秋水仙碱用于冠心病二级预防的新证据。
Med J Aust. 2022 May 2;216(8):385-387. doi: 10.5694/mja2.51488. Epub 2022 Apr 8.
2
Anti-inflammatory (Colchicine) Treatment for Secondary Prevention in Coronary Artery Disease: A Milestone has Been Met.用于冠状动脉疾病二级预防的抗炎（秋水仙碱）治疗：已达成一个里程碑。
J Cardiovasc Pharmacol. 2023 Oct 1;82(4):237-240. doi: 10.1097/FJC.0000000000001467.
3
Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.为什么秋水仙碱应该被考虑用于动脉粥样硬化的二级预防：概述。
Clin Ther. 2019 Jan;41(1):41-48. doi: 10.1016/j.clinthera.2018.11.016. Epub 2018 Dec 24.
4
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.低剂量秋水仙碱用于冠心病二级预防：JACC 本周综述主题。
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.
5
Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease.COLCOT和LoDoCo2研究的经验教训：秋水仙碱用于冠状动脉疾病的二级预防
Eur Heart J. 2021 Jul 21;42(28):2800-2801. doi: 10.1093/eurheartj/ehab020.
6
Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials.秋水仙碱用于冠心病二级预防的Meta 分析：随机对照试验研究。
Heart Lung Circ. 2022 May;31(5):685-695. doi: 10.1016/j.hlc.2021.09.017. Epub 2022 Jan 13.
7
Colchicine in coronary artery disease.秋水仙碱治疗冠状动脉疾病。
Postgrad Med J. 2022 Sep;98(1163):718-721. doi: 10.1136/postgradmedj-2020-139611. Epub 2021 Mar 29.
8
Colchicine in Stable Coronary Artery Disease.秋水仙碱在稳定型冠状动脉疾病中的应用。
Clin Ther. 2019 Jan;41(1):30-40. doi: 10.1016/j.clinthera.2018.09.011. Epub 2018 Nov 2.
9
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.稳定性冠心病患者低剂量秋水仙碱的疗效：LoDoCo2 试验的原理、设计和基线特征。
Am Heart J. 2019 Dec;218:46-56. doi: 10.1016/j.ahj.2019.09.011. Epub 2019 Oct 20.
10
Colchicine in the Management of Acute and Chronic Coronary Artery Disease.秋水仙碱在急性和慢性冠状动脉疾病治疗中的应用。
Curr Cardiol Rep. 2021 Jul 16;23(9):120. doi: 10.1007/s11886-021-01560-w.

引用本文的文献

1
[Colchicine-Phoenix from the ashes].[秋水仙碱——浴火重生]
Wien Klin Wochenschr. 2025 Feb;137(Suppl 1):1-33. doi: 10.1007/s00508-024-02490-7. Epub 2025 Feb 6.
2
Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management.秋水仙碱药物相互作用错误与误解：基于证据的管理改进建议。
Drug Saf. 2023 Mar;46(3):223-242. doi: 10.1007/s40264-022-01265-1. Epub 2022 Dec 15.

本文引用的文献

1
Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial.秋水仙碱用于急性冠脉综合征患者：澳大利亚COPS随机临床试验的两年随访
Circulation. 2021 Nov 9;144(19):1584-1586. doi: 10.1161/CIRCULATIONAHA.121.054610. Epub 2021 Nov 8.
2
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease.关于长期低剂量秋水仙碱在痛风和心血管疾病中的疗效和安全性的共识声明。
Am J Med. 2022 Jan;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025. Epub 2021 Aug 18.
3
Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE).拉丁美洲剩余心血代谢风险管理共识。由拉丁美洲脂质和心血代谢风险学会（ALALIP）编写的共识文件，得到了美洲心脏病学会（IASC）、国际动脉粥样硬化学会（IAS）和泛美内皮学会（PACE）的认可。
Arch Cardiol Mex. 2022 Jan 3;92(1):99-112. doi: 10.24875/ACM.21000005.
4
Colchicine and the heart.秋水仙碱与心脏。
Eur Heart J. 2021 Jul 21;42(28):2745-2760. doi: 10.1093/eurheartj/ehab221.
5
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.低剂量秋水仙碱治疗冠心病患者的疗效和安全性：随机试验的系统评价和荟萃分析。
Eur Heart J. 2021 Jul 21;42(28):2765-2775. doi: 10.1093/eurheartj/ehab115.
6
Colchicine in Patients with Chronic Coronary Disease.秋水仙碱治疗慢性冠心病
N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
7
Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability.从晶体透镜看动脉粥样硬化：动脉粥样硬化斑块中胆固醇晶体结构的演变如何改变其稳定性。
J Clin Lipidol. 2020 Sep-Oct;14(5):619-630. doi: 10.1016/j.jacl.2020.07.003. Epub 2020 Jul 11.
8
Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials.口服秋水仙碱使用期间的不良反应：随机对照试验的系统评价和荟萃分析。
Arthritis Res Ther. 2020 Feb 13;22(1):28. doi: 10.1186/s13075-020-2120-7.
9
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
10
Statins: Then and Now.他汀类药物：过去与现在。
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):23-31. doi: 10.14797/mdcj-15-1-23.

Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease.

作者信息

Nidorf Stefan M, Layland Jamie, Robinson Philip C, Patel Sanjay, Psaltis Peter J, Thompson Peter L

机构信息

Genesis Care, Perth, WA.

Heart and Vascular Research Institute, Harry Perkins Institute of Medical Research, Perth, WA.

出版信息

Med J Aust. 2022 May 2;216(8):385-387. doi: 10.5694/mja2.51488. Epub 2022 Apr 8.

DOI:10.5694/mja2.51488
PMID:35393699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9543631/
Abstract
摘要